Overview

* Doximity ( DOCS ) fiscal Q2 revenue grows 23% yr/yr, beating analysts' expectations

* Adjusted EBITDA for fiscal Q2 beats consensus, rising 32% yr/yr

* Company highlights growth in AI tools and user engagement

Outlook

* Doximity ( DOCS ) sees Q3 revenue between $180 mln and $181 mln

* Company expects Q3 adjusted EBITDA between $103 mln and $104 mln

* Doximity ( DOCS ) projects FY2026 revenue between $640 mln and $646 mln

* Company anticipates FY2026 adjusted EBITDA between $351 mln and $357 mln

Result Drivers

* AI TOOL ADOPTION - Co attributes revenue growth to increased use of AI tools, with AI Scribe and DoxGPT users growing over 50% from prior qtr

* USER ENGAGEMENT - Record 650,000 prescribers used workflow tools, contributing to revenue growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $168.53 $157.61

Revenue mln mln (18

Analysts

)

Q2 Net $62.06

Income mln

Q2 Beat $100.83 $87.54

Adjusted mln mln (18

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 7 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the software peer group is "buy"

* Wall Street's median 12-month price target for Doximity Inc ( DOCS ) is $72.50, about 11.7% above its November 5 closing price of $63.99

* The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 39 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)